Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;8(Suppl 6):S612-S617.
doi: 10.21037/tcr.2019.06.21.

Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study

Sara Elena Rebuzzi  1   2 , Francesco Facchinetti  3 , Marcello Tiseo  1   4
Affiliations
Editorial

Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study

Sara Elena Rebuzzi et al. Transl Cancer Res. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: M Tiseo declares advisory boards and/or speakers’ fee for Astra-Zeneca, BMS, MSD, Boehringer Ingelheim, Takeda. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab vs. chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Planchard D, Popat St, Kerr K, et al. Metastatic Non-Small-Cell Lung Cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv192-237. 10.1093/annonc/mdy275 - DOI - PubMed
    1. Hellmann MD, Ciuleanu TE, Adam Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018;378:2093-104. 10.1056/NEJMoa1801946 - DOI - PMC - PubMed
    1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078-92. 10.1056/NEJMoa1801005 - DOI - PubMed
    1. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non - small-cell lung cancer. N Engl J Med 2018;379:2040-51. 10.1056/NEJMoa1810865 - DOI - PubMed